Completed PHASE2 INTERVENTIONAL 2-arm NCT00788073

Safety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X Syndrome

A Double-Blind, Placebo-Controlled, Crossover, Flexible-Dose Evaluation of the Efficacy, Safety and Tolerability of STX209 in the Treatment of Irritability in Subjects With Fragile X Syndrome

Sponsor: Seaside Therapeutics, Inc.

Conditions Fragile X Syndrome

Interventions Placebo STX209

Updated 6 times since 2017 Last updated: Mar 22, 2013 Started: Nov 30, 2008 Primary completion: Mar 31, 2010 Completion: May 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Fragile X Syndrome and is currently completed. Seaside Therapeutics, Inc. leads this study, which shows 6 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Nov 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Seaside Therapeutics, Inc.

Data source: Seaside Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Boston, United States , Chapel Hill, United States , Chicago, United States , Houston, United States , Indianapolis, United States , Los Angeles, United States , Media, United States , Nashville, United States , Phoenix, United States , Sacramento, United States and 2 more locations